Analyzing Proteon Therapeutics (PRTO) and Neurocrine Biosciences (NBIX)

Proteon Therapeutics (NASDAQ: PRTO) and Neurocrine Biosciences (NASDAQ:NBIX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Profitability

Get Proteon Therapeutics alerts:

This table compares Proteon Therapeutics and Neurocrine Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Proteon Therapeutics N/A -172.29% -71.78%
Neurocrine Biosciences -45.56% -29.67% -13.46%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Proteon Therapeutics and Neurocrine Biosciences, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Proteon Therapeutics 0 2 2 0 2.50
Neurocrine Biosciences 0 0 13 0 3.00

Proteon Therapeutics currently has a consensus target price of $3.00, suggesting a potential upside of 9.09%. Neurocrine Biosciences has a consensus target price of $102.77, suggesting a potential upside of 0.96%. Given Proteon Therapeutics’ higher possible upside, equities research analysts plainly believe Proteon Therapeutics is more favorable than Neurocrine Biosciences.

Risk and Volatility

Proteon Therapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500.

Valuation and Earnings

This table compares Proteon Therapeutics and Neurocrine Biosciences’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Proteon Therapeutics N/A N/A -$29.96 million ($2.13) -1.29
Neurocrine Biosciences $161.63 million 56.62 -$142.54 million ($1.62) -62.83

Proteon Therapeutics has higher earnings, but lower revenue than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Proteon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

50.6% of Proteon Therapeutics shares are owned by institutional investors. 45.7% of Proteon Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to improve hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL ? Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Leave a Reply

Your email address will not be published. Required fields are marked *